Ansgar Hebborn
Is the European Harmonisation of HTA Worth Pursuing?
February 23 by Pharmaceuticals & Biotechnology EditorAnsgar Hebborn, Head of the Global Payer & HTA Program Policy at F Hoffmann-La Roche, joins Tim Haïdar from Pharma IQ, to analyse major trends and implications for the research-ba...
HTA: Past, Present and Future
April 19 by Pharmaceuticals & Biotechnology EditorAnsgar Hebborn, Head of the Global Payer & HTA Program Policy at F Hoffmann-La Roche, joins Pharma IQ to analyse major trends and implications for the research-based pharmaceutical industry....
